remdesivir

Read More
Less
A lab technicians holds the coronavirus disease (COVID-19) treatment drug "Remdesivir" at Eva Pharma

US hospitals turn down remdesivir, limit use to sickest COVID-19 patients

The Food and Drug Administration has allowed more liberal remdesivir use, but 6 out of 8 major hospital systems contacted by Reuters said they were not using it for moderate cases.

By REUTERS
12/09/2020
A lab technicians holds the coronavirus disease (COVID-19) treatment drug "Remdesivir" at Eva Pharma

FDA approves expanded use of remdesivir in moderate COVID-19 patients

The drug was authorized in May for use in patients with a severe form of the illness, after trial data showed the antiviral drug helped shorten hospital recovery time.

By REUTERS
29/08/2020
A lab technicians holds the coronavirus disease (COVID-19) treatment drug "Remdesivir" at Eva Pharma

Israel secures more Remdesivir to treat COVID-19 patients

Several hospitals, including Sheba Medical Center at Tel Hashomer and Rambam Medical Center in Haifa, had reported they were out.

Gates: COVID-19 meds should to go to those in need, not 'highest bidder'

"We need leaders to make these hard decisions about distributing based on equity, not just on market-driven factors."

By REUTERS
11/07/2020

Gilead says additional data on remdesivir shows improved clinical recovery

Findings from the analysis of its late-stage study showed that 74.4% of remdesivir-treated patients recovered by Day 14 versus 59.0% of patients receiving standard of care, the company said.

By REUTERS
10/07/2020
Vials of investigational coronavirus disease (COVID-19) treatment drug remdesivir are capped at a Gi

Gilead's coronavirus antiviral remdesivir gets conditional EU clearance

Remdesivir is in high demand after the intravenously-administered medicine helped to shorten hospital recovery times in a clinical trial.

By REUTERS
04/07/2020
Vials of investigational coronavirus disease (COVID-19) treatment drug remdesivir are capped at a Gi

Gilead prices COVID-19 drug remdesivir at $2,340 per patient

Remdesivir is expected to be in high demand as one of the only treatments so far shown to alter the course of COVID-19.

By REUTERS
30/06/2020
Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use and privacy policy